Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Boehringer Ingelheim, Immunitas Therapeutics license preclinical antibody for inflammatory conditions, €407.5M ($478M) milestones
Licensing deal, autoimmune, antibody, milestone payments, royalties - Read more

Arvinas, Pfizer license Veppanu to Rigel Pharmaceuticals for $75M upfront, $320M milestones
Licensing deal, oncology, small molecule, milestone payments, royalties - Read more

Bristol Myers Squibb, Hengrui Pharma build 13-asset oncology and immune disease pipeline in $15.2B deal
Co-development, oncology, autoimmune, small molecule, milestone payments, royalties - Read more

Boehringer Ingelheim, Brainomix expand AI imaging partnership with prospective pulmonary fibrosis study PROGRESS-PPF
Research collaboration, AI/ML, rare disease, diagnostics, small molecule - Read more

CSL Seqirus, PAHO sign multi-year pandemic influenza preparedness agreement for Latin America and Caribbean
Manufacturing agreement, vaccine, infectious disease, pandemic preparedness, supply agreement - Read more

Ribo Life Science, Insilico Medicine partner on AI-driven siRNA therapies and small molecule drug co-development
Co-development, AI/ML, siRNA, small molecule, drug discovery - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Alkermes' Lumryz (sodium oxybate) meets all Ph3 endpoints in idiopathic hypersomnia, fueling FDA filing plans
Small molecule, neurological, sodium oxybate, idiopathic hypersomnia, narcolepsy, sleep disorder - Read more

Enterprise Therapeutics' ETD001 (ETD001) meets Ph2 primary endpoint, improving lung function in cystic fibrosis patients unresponsive to CFTR modulators
Small molecule, respiratory disease, inhaled therapy, ENaC blocker, cystic fibrosis - Read more

BridgeBio's Attruby (acoramidis) Ph3 data suggest superiority over Pfizer's tafamidis in transthyretin amyloidosis cardiomyopathy
Small molecule, cardiovascular, transthyretin stabilizer, transthyretin amyloidosis cardiomyopathy, TTR protein target - Read more

Alnylam Pharmaceuticals' Amvuttra (vutrisiran) Ph3 data shows consistent TTR-silencing benefit across transthyretin amyloid cardiomyopathy patient populations
RNA interference, cardiovascular, siRNA, transthyretin amyloidosis, cardiomyopathy, TTR silencer - Read more

Eli Lilly's Foundayo (orforglipron) and Zepbound (tirzepatide) Ph3 trials show sustained weight-loss maintenance in obesity
Small molecule, metabolic, GLP-1 receptor agonist, obesity, weight maintenance, incretin therapy - Read more

Isomorphic Labs raises $2.1B Series B to develop AI drug design engine, accelerate pipeline
AI/ML platform, drug discovery, small molecule, platform-enabled - Read more

Tolemy Bio raises €1.4M ($1.65M) pre-seed to advance AI-driven cell biology platform
Cell biology, AI/ML platform, software platform, drug discovery, virtual cell modeling - Read more

Forus raises $160M to build AI-powered network connecting doctors, pharmacies, and biopharma
AI/ML platform, software platform, data analytics, biopharma services - Read more

Infex Therapeutics secures £4.3M funding to advance anti-infective pipeline targeting drug-resistant infections
Infectious disease, antimicrobial resistance, small molecule, clinical-stage - Read more

CEL-SCI prices $7.2M public offering to advance Multikine cancer immunotherapy development
Oncology, cancer immunotherapy, clinical-stage, immunotherapy - Read more

EU Council and Parliament reach provisional agreement on Critical Medicines Act to combat drug shortages
Small molecule, rare disease, operational, strategic - Read more

Charles River Laboratories launches AI digital pathology platform, cutting turnaround times by at least one week
AI diagnostics, pathology, operational, strategic - Read more

FDA launches drug repurposing program targeting metabolic, neurodegenerative, rare diseases, and other unmet medical needs
Drug repurposing, rare disease, metabolic, neurodegenerative - Read more

SMC recommends enfortumab vedotin plus pembrolizumab for metastatic bladder cancer on NHS Scotland
Antibody-drug conjugate, oncology, regulatory, reimbursement - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

AstraZeneca's (eneboparatide) PTH-1 receptor agonist falls short in Ph3 chronic hypoparathyroidism trial due to immunogenicity
Protein therapy, metabolic, PTH-1 receptor agonist, hypoparathyroidism, immunogenicity - Read more

Bayer's Eylea sales drop 24% amid mounting biosimilar competition in Q1
Monoclonal antibody, ophthalmology, competitive, revenue impact - Read more

BioMarin Pharmaceutical cuts 58 roles at Amicus Therapeutics' Princeton HQ following $4.8B acquisition
Enzyme replacement therapy, rare disease, major transaction, operational, cost reduction - Read more

Bayer discontinues Ph1 ANP-based therapy (BAY 2701250) for pulmonary hypertension and diabetic neuropathic pain drug following portfolio review decisions
Protein therapy, cardiovascular, small molecule, hypertension, neuropathic pain, GPR84 antagonist - Read more

FDA Commissioner Marty Makary resigns after turbulent tenure marked by White House tensions
Regulatory leadership, strategic, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here